Selene Therapeutics

Company Overview

Snapshot

Founded in September 2020 by Inna Slutsky and Neta Pessah, Selene Therapeutics operates with 1–10 employees. The company has secured funding across two rounds, with a notable grant received from the Israel Innovation Authority in June 2024.

Business overview

Selene Therapeutics is a Health Tech & Life Sciences company focused on developing novel therapeutic strategies for refractory epilepsy. The company's core technology involves creating small molecule inhibitors for dihydroorotate dehydrogenase, a mitochondrial enzyme, to regulate neuronal activity. Selene Therapeutics operates within the Pharmaceuticals sector, targeting the drug discovery and development market.

Company Intelligence Q&A

What is Selene Therapeutics' primary focus?

Selene Therapeutics is dedicated to developing new therapeutic strategies for treating refractory epilepsy by regulating the neuronal activity set point through reducing the neuronal mean firing rate.

What is the core technology behind Selene Therapeutics' approach?

The company aims to develop small molecules that act as inhibitors of dihydroorotate dehydrogenase, a mitochondrial enzyme involved in key cellular homeostatic processes.

When was Selene Therapeutics founded and by whom?

Selene Therapeutics was founded in September 2020 by Inna Slutsky and Neta Pessah.

Has Selene Therapeutics received any grants?

In June 2024, Selene Therapeutics secured a grant from the Israel Innovation Authority.

Which incubator is Selene Therapeutics a part of?

Selene Therapeutics is part of the FuturX biotech incubator in Ness Ziona. FuturX also participated as an investor in October 2020, alongside RMGP Biopharma Investment Fund.